ReviewFrontiers in endocrinology2026
Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular-kidney-metabolic (CKM) syndrome reflects the complex interplay among cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. GLP-1 receptor agonists and tirzepatide have emerged as important therapeutic options within CKM syndrome, although the strength and maturity of evidence differ across individual agents and cardiovascular and kidney outcomes. This narrative review summarizes current evidence on the cardiovascular and kidney effects of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide. Large randomized controlled trials have established reductions in major adverse cardiovascular events with several GLP-1 receptor agonists, while dedicated evidence for clinically meaningful chronic kidney disease progression is currently strongest for semaglutide. Cardiovascular benefits of semaglutide have also been demonstrated in individuals with overweight or obesity without type 2 diabetes, supporting effects beyond glucose lowering. Tirzepatide provides substantial improvements in glycemic control and body weight, with expanding evidence supporting cardiovascular benefit, including particularly encouraging findings in obesity-related heart failure with preserved ejection fraction. In contrast, its kidney evidence remains less mature and is derived predominantly from secondary and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.